Cargando…
Diagnostic accuracy of circulating-free DNA for the determination of MYCN amplification status in advanced-stage neuroblastoma: a systematic review and meta-analysis
BACKGROUND: MYCN amplification (MNA) is the strongest indicator of poor prognosis in neuroblastoma (NB). This meta-analysis aims to determine the diagnostic accuracy of MNA analysis in circulating-free DNA (cfDNA) from advanced-stage NB patients. METHODS: A systematic review of electronic databases...
Autores principales: | Trigg, Ricky M., Turner, Suzanne D., Shaw, Jacqueline A., Jahangiri, Leila |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109036/ https://www.ncbi.nlm.nih.gov/pubmed/32015512 http://dx.doi.org/10.1038/s41416-020-0740-y |
Ejemplares similares
-
Opportunities and challenges of circulating biomarkers in neuroblastoma
por: Trigg, Ricky M., et al.
Publicado: (2019) -
MYCN Amplifications and Metabolic Rewiring in Neuroblastoma
por: Pouliou, Marialena, et al.
Publicado: (2023) -
MYCN amplification and ATRX mutations are incompatible in neuroblastoma
por: Zeineldin, Maged, et al.
Publicado: (2020) -
Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma
por: Su, Yan, et al.
Publicado: (2020) -
The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status
por: Trigg, Ricky M., et al.
Publicado: (2019)